PALO
ALTO, Calif., Sept. 22,
2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc.
(Nasdaq: EIGR), a commercial-stage biopharmaceutical company
focused on the development of innovative therapies for hepatitis
delta virus (HDV) and other serious diseases, today announced that
David Cory, President and CEO, will
present a company overview at the 2022 Ladenburg Thalmann
Healthcare Conference on Thursday, September
29, 2022 at 1:00 PM ET in
New York City. Eiger will also
host one-on-one meetings with investors at the conference.
A live webcast of the presentation will be available on the
Investors section of the Eiger BioPharmaceuticals website at
www.eigerbio.com, and a replay will be available on the website for
at least 90 days.
About Eiger
Eiger is a commercial-stage biopharmaceutical company focused on
the development of innovative therapies for hepatitis delta virus
(HDV) and other serious diseases. The Eiger HDV platform includes
two first-in-class therapies in Phase 3 that target critical host
processes involved in viral replication. All five Eiger rare
disease programs have been granted FDA Breakthrough Therapy
designation: lonafarnib and peginterferon lambda for HDV, Zokinvy
for progeria, and avexitide for both congenital hyperinsulinism and
post-bariatric hypoglycemia.
For additional information about Eiger and its clinical
programs, please visit www.eigerbio.com.
Contacts
Investors:
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Media:
Sarah Mathieson
SVP, Corporate Affairs
smathieson@eigerbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-2022-ladenburg-thalmann-healthcare-conference-301630711.html
SOURCE Eiger BioPharmaceuticals, Inc.